ClinicalTrials.gg
RecruitingNCT05805696Updated May 10, 2024

Treatment and Mapping of Impostor Phenomenon

An interventional study of Impostor tasks in Dermatoses, Vestibulodynia and Hyperhidrosis, sponsored by Umeå University. Recruiting at 2 sites in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-10.

Primary conditionHyperhidrosisRegistry: Skin DiseasesReclassifiedWhy we changed it
Registry
Skin Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hyperhidrosis
Why
  1. The study's listed conditions name Hyperhidrosis, a narrower term within Skin Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Umeå University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this study is to evaluate persons/patients with different skin diseases or pain to evaluate whether unhealthy perfectionism, stress, anxiety, impostor phenomenon (inability to realistically assess your competence and skills) and lack of self-compassion (a positive attitude towards ourselves), have impact on symptoms, handling, and treatment regarding some dermatological diseases/pain.

Read the detailed description

The investigators have noticed that these conditions are common among patients attending the clinic. The investigators therefore want to do mapping of the occurrence and make an intervention to be able to change and evaluate handling of these patients. The hypothesis is that there is a connection between these conditions and that they are all part of the patients´ disease. The study will be done by using validated questionnaires which are answered anonymously using a code, that is known only by the participant, and with exercises/interventions for five or ten weeks. The questionnaires and interventions are formerly used in several international studies and by the investigators in populations of healthy persons with different professions.

Examples of diseases is localised provoked vulvodynia (former vulvar vestibulitis) a state of pain that mainly affects young women. The symptoms are localized to the vulvar vestibulum and provoked by touch and experienced by the patient as pain or burning. The aetiology is not clearly known but probably due to both physical and psychological factors. Treatment is due to several strategies like treating the pain, rehabilitation of the perineum, and psychosocial support. Persons with this type of pain will also answer a short questionnaire regarding their symptoms. Another example is hyperhidrosis is excessive sweating without known cause. Hyperhidrosis may be primary focal or multifocal with debut in childhood. Secondary hyperhidrosis is often due to another disease. Hyperhidrosis often means big stress on mental health but may also affect physical functions. Persons with hyperhidrosis estimate their quality of life equal with those affected by severe acne or psoriasis.

The investigators´ ongoing research with mapping of these different traits of character shows that the occurrence is increasing, but no treatment has so far been available in Sweden. The investigators therefore want to evaluate whether treatment by intervention with one or two exercises each week may diminish the occurrence of impostor phenomenon and to be able to influence the disease.

The questionnaires that will be used are "Self-Compassion scale short version" (SCS-SF), "Clance Impostor Phenomenon scale" (CIPS), "Perceived Stress scale 4" (PSS-4), "Generalized Anxiety Disorder-2" (GAD-2), and "Clinical Perfectionism Questionnaire short form" (CPQ-SF). These questionnaires are validated by other investigators and used in several international research studies. The questionnaires have already been translated from English to Swedish, except CIPS that has been translated and back-translated. There will also be questions on gender, age, and term. The software for statistical analyses is Statistical Package for the Social Sciences (SPSS) version 27 from International Business Machines Corporation (IBM).

Before starting treatment, the participants will get a web-based survey including twenty questions about impostor phenomenon (CIPS), six questions about stress and anxiety (PSS-4 and GAD-2), twelve questions about self-compassion (SCS-SF) and six questions about perfectionism (CPQ-SF). The questionnaires are repeated week twelve and 24 after intervention. After inclusion and answering the first questionnaire the persons are asked to participate in a series of one or two interventions, 30 minutes each, every week for ten or five weeks respectively.

02

Conditions studied

  • Dermatoses
  • Vestibulodynia
  • Hyperhidrosis
  • Pain Syndrome

Browse trials for

03

In context

Hyperhidrosis Reclassified

111 studies on the registry are indexed under Hyperhidrosis; 10 are open to participants now.

This study's planned enrollment of 20 is below the median of 50 across 99 interventional studies indexed under Hyperhidrosis.

Browse Hyperhidrosis studies →

Lead sponsor

Umeå University is the lead sponsor of 272 studies on the registry; 60 are open to participants now.

Compared within Hyperhidrosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Skin Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients attending the Dept of Dermatology and Venereology
  • Diagnosed with a dermatological disease

Exclusion criteria

Exclusion criteria

  • Age under 18
  • Not able to read/speak Swedish
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Treatment for five weeks

    The patients will get questionnaires before and 12 weeks and 24 weeks after intervention. The intervention will last for 5 weeks.

    Behavioral: Impostor tasks

Interventions

  • BehavioralImpostor tasks

    Tasks to do every week

06

What researchers measure

Primary outcomes

  1. Signs of impostor

    Questionnaire regarding impostor

    Time frame: At the beginning, after 12 and 24 weeks

  2. Signs of disease/pain

    Questionnaire regarding symptoms

    Time frame: At the beginning, after 12 and 24 weeks

07

Study locations

1 of 2 sites recruiting
  • Umea University
    Umea, 90185, Sweden
    Recruiting
    • Elisabet Nylander, MD, PhD · Contactelisabet.nylander@umu.se · 702668528
    • Jens Boman, MD,PhD · Contact767772650
  • Dept of Public Health and Clinical Medicine, Umeå University
    Umeå, 90186, Sweden
    Active, not recruiting

    Not enrolling at this site.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05805696
Lead sponsor
Umeå University
Responsible party
Elisabet Nylander (Professor/senior consultant, Umeå University) — Principal investigator
First posted
Apr 10, 2023
Start date
May 15, 2024 (estimated)
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
May 10, 2024

Study contacts

Elisabet Nylander, MD, PhD
Contact
elisabet.nylander@umu.se
+46907859191
Jens Boman, MD, PhD
Contact
jens.boman@umu.se
+46907851111

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion